Cementless Acetabular Components Implanted with a High Hip Center in Total Hip Arthroplasty for Crowe II and III Hip Dysplasia
IRB Number: 11176
inactiveMay 24, 2012
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
- Amar S. Ranawat MD
Co-Investigators
- Amar S. Ranawat MD
- Danyal H. Nawabi MD
- Matin Lendhey
Summary
50 patients. Minimum 10 year follow-up.
Inclusion/Exclusion Criteria
Inclusion:
Age 18-80 years, Crowe II and II dysplasia of the Hip, THA with a high hip center
Exclusion:
Revision THA for dysplasia, Crowe I and IV dysplasia
Contact Information
Chitranjan S. Ranawat MD
RanawatC@hss.edu
646.797.8700